HomeCompareACORQ vs JEPQ

ACORQ vs JEPQ: Dividend Comparison 2026

ACORQ yields 20000.00% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACORQ wins by $52481917574412746752.00M in total portfolio value
10 years
ACORQ
ACORQ
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ACORQ calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — ACORQ vs JEPQ

📍 ACORQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACORQJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACORQ + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACORQ pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACORQ
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, ACORQ beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACORQ + JEPQ for your $10,000?

ACORQ: 50%JEPQ: 50%
100% JEPQ50/50100% ACORQ
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACORQ buys
0
JEPQ buys
0
No recent congressional trades found for ACORQ or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACORQJEPQ
Forward yield20000.00%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52481917574412746752.00M$44.8K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$2,152.59
Total dividends collected$52448189483771600896.00M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ACORQ vs JEPQ ($10,000, DRIP)

YearACORQ PortfolioACORQ Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,930$1,110.39+$2.00MACORQ
2$377,983,225$375,831,775.70$14,133$1,224.34+$377.97MACORQ
3$66,433,479,469$66,029,037,418.28$16,632$1,340.46+$66433.46MACORQ
4$10,916,985,471,987$10,845,901,648,955.73$19,454$1,457.97+$10916985.45MACORQ
5$1,677,384,363,769,318$1,665,703,189,314,291.80$22,626$1,576.08+$1677384363.75MACORQ
6$240,985,175,079,139,100$239,190,373,809,905,920.00$26,175$1,694.09+$240985175079.11MACORQ
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$30,133$1,811.32+$32373573631143.66MACORQ
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$34,531$1,927.17+$4066766648320630.00MACORQ
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$39,403$2,041.08+$477730483406513344.00MACORQ
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$44,787$2,152.59+$52481917574412746752.00MACORQ

ACORQ vs JEPQ: Complete Analysis 2026

ACORQStock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full ACORQ Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this ACORQ vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACORQ vs SCHDACORQ vs JEPIACORQ vs OACORQ vs KOACORQ vs MAINACORQ vs XYLDACORQ vs QYLDACORQ vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.